Erectile Dysfunction - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 101 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Erectile Dysfunction - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H2 2014', provides an overview of the Erectile Dysfunction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Erectile Dysfunction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Erectile Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Erectile Dysfunction Overview 9
Therapeutics Development 10
Pipeline Products for Erectile Dysfunction - Overview 10
Pipeline Products for Erectile Dysfunction - Comparative Analysis 11
Erectile Dysfunction - Therapeutics under Development by Companies 12
Erectile Dysfunction - Therapeutics under Investigation by Universities/Institutes 15
Erectile Dysfunction - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Erectile Dysfunction - Products under Development by Companies 20
Erectile Dysfunction - Products under Investigation by Universities/Institutes 21
Erectile Dysfunction - Companies Involved in Therapeutics Development 22
Bioheart, Inc. 22
Suda Ltd 23
Acorda Therapeutics, Inc. 24
IntelGenx Corp. 25
Apricus Biosciences, Inc. 26
Palatin Technologies, Inc. 27
Yungjin Pharm Ind. Co., Ltd. 28
Yuhan Corporation 29
NAL Pharmaceuticals Ltd. 30
Biolab Sanus Farmaceutica Ltda. 31
Pharmicell Co., Ltd. 32
Pacific Therapeutics Ltd. 33
Aprogen, Inc. 34
Corridor Pharmaceuticals Inc. 35
Furiex Pharmaceuticals, Inc. 36
Sagene Pharmaceuticals, Inc. 37
LondonPharma Ltd 38
Mezzion Pharma Co. Ltd. 39
Erectile Dysfunction - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Combination Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
alprostadil - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
udenafil - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
dapoxetine hydrochloride - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
MED-2002 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
YHD-1023 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
sildenafil citrate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
tadalafil - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
YBH-1603 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PL-6983 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
cimaglermin alfa - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
selegiline + PDE-5 Inhibitor - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
AP-102 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Next Generation Melanocortin Receptor IV Agonist - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Immpocellgram - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
TPN-729 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
BL-214 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
AdipoCell - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
sildenafil citrate - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
tadalafil - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
sildenafil citrate - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
sildenafil citrate - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Erectile Dysfunction - Recent Pipeline Updates 82
Erectile Dysfunction - Dormant Projects 92
Erectile Dysfunction - Discontinued Products 93
Erectile Dysfunction - Product Development Milestones 94
Featured News & Press Releases 94
Aug 18, 2014: Apricus Biosciences Announces the Launch of Its Topical Treatment for Erectile Dysfunction Vitaros in Germany by Hexal 94
Aug 04, 2014: Apricus Biosciences Announces the Launch of Its Topical Treatment for Erectile Dysfunction Vitaros in Sweden by Sandoz 94
Jul 09, 2014: New Grant Enables Humanetics to Evaluate Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients 95
Jun 16, 2014: Apricus Biosciences Announces the Launch of Its Topical Treatment for Erectile Dysfunction Vitaros in the United Kingdom 95
Jun 13, 2014: Chinese Drugmakers To Manufacture Generic Viagra As Pfizer's Patent Nears Expiry 96
Apr 24, 2014: Apricus Biosciences Announces National Phase Approval for Vitaros in Spain 96
Apr 16, 2014: Apricus Biosciences' Partner in the United Kingdom Accepts First Shipment of Vitaros 97
Apr 07, 2014: Apricus Biosciences and Its European Partners to Sponsor Symposium on Vitaros at the European Association of Urology Congress, Stockholm 97
Apr 03, 2014: Apricus Biosciences Announces National Phase Approval for Vitaros in Luxembourg 98
Feb 24, 2014: IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm Tadalafil Product 99
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 101
Disclaimer 101

List of Tables
Number of Products under Development for Erectile Dysfunction, H2 2014 10
Number of Products under Development for Erectile Dysfunction - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Development by Companies, H2 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Late Stage Development, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Development, H2 2014 18
Comparative Analysis by Unknown Stage Development, H2 2014 19
Products under Development by Companies, H2 2014 20
Products under Investigation by Universities/Institutes, H2 2014 21
Erectile Dysfunction - Pipeline by Bioheart, Inc., H2 2014 22
Erectile Dysfunction - Pipeline by Suda Ltd., H2 2014 23
Erectile Dysfunction - Pipeline by Acorda Therapeutics, Inc., H2 2014 24
Erectile Dysfunction - Pipeline by IntelGenx Corp., H2 2014 25
Erectile Dysfunction - Pipeline by Apricus Biosciences, Inc., H2 2014 26
Erectile Dysfunction - Pipeline by Palatin Technologies, Inc., H2 2014 27
Erectile Dysfunction - Pipeline by Yungjin Pharm Ind. Co., Ltd., H2 2014 28
Erectile Dysfunction - Pipeline by Yuhan Corporation, H2 2014 29
Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd., H2 2014 30
Erectile Dysfunction - Pipeline by Biolab Sanus Farmaceutica Ltda., H2 2014 31
Erectile Dysfunction - Pipeline by Pharmicell Co., Ltd., H2 2014 32
Erectile Dysfunction - Pipeline by Pacific Therapeutics Ltd., H2 2014 33
Erectile Dysfunction - Pipeline by Aprogen, Inc., H2 2014 34
Erectile Dysfunction - Pipeline by Corridor Pharmaceuticals Inc., H2 2014 35
Erectile Dysfunction - Pipeline by Furiex Pharmaceuticals, Inc., H2 2014 36
Erectile Dysfunction - Pipeline by Sagene Pharmaceuticals, Inc., H2 2014 37
Erectile Dysfunction - Pipeline by LondonPharma Ltd, H2 2014 38
Erectile Dysfunction - Pipeline by Mezzion Pharma Co. Ltd., H2 2014 39
Assessment by Monotherapy Products, H2 2014 40
Assessment by Combination Products, H2 2014 41
Number of Products by Stage and Target, H2 2014 43
Number of Products by Stage and Mechanism of Action, H2 2014 45
Number of Products by Stage and Route of Administration, H2 2014 47
Number of Products by Stage and Molecule Type, H2 2014 49
Erectile Dysfunction Therapeutics - Recent Pipeline Updates, H2 2014 82
Erectile Dysfunction - Dormant Projects, H2 2014 92
Erectile Dysfunction - Discontinued Products, H2 2014 93